Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals Announces Final Lomitapide AEGR-733 Phase II Data
Published in Cardiovascular Business Week, June 30th, 2009
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, announced final data from three separate Phase II trials involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein inhibitor (MTP-I) small molecule drug. The final data was recently presented at the American Diabetes Association's "69th Scientific Sessions" in New Orleans, LA on June 7, 2009 and the International Symposium on Atherosclerosis (ISA) in Boston, MA on June 15, 2009.
The three trials ranged in duration from 8 to 12 weeks and collected clinical data on more than 460...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
More Articles from Cardiovascular Business Week
- Abdominal Aortic Aneurysm
Arizona Heart Institute Enrolls First Patient in Anaconda(TM) Investigational Study for the Treatment of Abdominal Aortic Aneurysm - Acute Pancreatitis
Glybera(TM) Shows Long-Term Health Benefits - Amarin Corporation plc
Amarin Announces Results from Exploratory Phase 2a Study of EN101 in Myasthenia Gravis - Atherosclerosis
diaDexus Announces Data on Lp-PLA2 to be Presented at International Symposium on Atherosclerosis - Atherosclerosis
Genomas Presents Drug-Specific Genetic Determinants of Statin Safety and Efficacy at the XV International Symposium on Atherosclerosis - Beaumont
Beaumont and Blue Cross Blue Shield of Michigan Announce Study Findings: Radiation for Heart Test Can Be Cut More Than Half - More from this issue of Cardiovascular Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
